Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Add To Watchlist

Recent & Breaking News (NDAQ:RDHL)

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

PR Newswire April 2, 2024

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

PR Newswire March 11, 2024

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

PR Newswire March 5, 2024

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

PR Newswire February 20, 2024

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

PR Newswire January 26, 2024

RedHill Biopharma Announces $8 Million Registered Direct Offering

PR Newswire January 25, 2024

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

PR Newswire January 25, 2024

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

PR Newswire December 20, 2023

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire December 12, 2023

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

PR Newswire December 4, 2023

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

PR Newswire November 27, 2023

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

PR Newswire November 14, 2023

RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study

PR Newswire October 3, 2023

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

PR Newswire September 22, 2023

RedHill Announces FDA sNDA Approval for Talicia®

PR Newswire September 18, 2023

RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)

PR Newswire September 5, 2023

RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights

PR Newswire August 17, 2023

RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.

PR Newswire August 1, 2023

RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA

PR Newswire July 31, 2023

RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise

PR Newswire July 25, 2023